Company Overview of The Multiple Myeloma Research Foundation, Inc
Key Executives for The Multiple Myeloma Research Foundation, Inc
Chief Executive Officer and President
Vice President of Communications
Compensation as of Fiscal Year 2016.
The Multiple Myeloma Research Foundation, Inc Key Developments
The Multiple Myeloma Research Foundation, Inc Announces the Collaboration with Memorial Sloan Kettering Cancer Center to Launch a New Clinical Trial for Multiple Myeloma (MM) Patients
Sep 13 16
The Multiple Myeloma Research Foundation Inc. announced a collaboration with Memorial Sloan Kettering Cancer Center to launch a new clinical trial for multiple myeloma (MM) patients. The trial, Carfilzomib, Lenalidomide, Dexamethasone in Newly-Diagnosed Multiple Myeloma: a Translational MRD Study, will integrate highly effective, modern combination therapy with genetic sequencing, to help define predictors of sustained MRD negativity. MRD is defined as the level of disease still detectable in MM patients after their treatment regimen is completed. Recent work has shown that very low or undetectable levels of MRD after completion of treatment (i.e., a “deep response”) is associated with improved patient outcomes including longer survival. MRD measurement may offer a faster and more accurate assessment of how effective a treatment is in an individual patient; use of this test, pending approval by the US Food and Drug Administration, could allow clinical trials to proceed more rapidly, thereby cutting costs and potentially speeding new treatments to patients more quickly than ever before. The sensitivity of MRD measurement also holds the promise to help doctors determine –in the coming future- if and when treatment may be stopped or re-started based on a patient’s MRD status.
The Multiple Myeloma Research Foundation Announces Management Changes
Feb 3 16
The Multiple Myeloma Research Foundation announced four appointments to its governing board and executive team. The appointees will work with long-standing MMRF leadership team, who have played a critical role in advancing the foundation's end-to-end precision medicine model. Paul Giusti has been named as President and Chief Executive Officer of the MMRF. Mr. Giusti, who most recently served as Chief Executive Officer of Structural Graphics, has more than 30 years of experience as a business leader and entrepreneur. Rob Miani has been named as Chief Financial Officer of the MMRF. Mr. Miani most recently served as Vice President of Finance and Corporate Controller of Aptuit, LLC. He brings to the MMRF more than 20 years of operating experience in both the private and public sectors. Michael Mortimer, Executive Partner and Founder of Global Healthcare Opportunities, LLP, has been named as Chairman of the MMRF Board of Directors. Mr. Mortimer has more than 25 years of global operating and management experience, most recently at Quintiles, where he served as Executive Vice President. Lori Marcus, founder of Courtyard Connections, has been named as Vice Chairwoman of the MMRF Board of Directors. Ms. Marcus has more than 30 years of marketing expertise, formerly serving as Chief Global Brand and Product Officer at Keurig Green Mountain and Senior Vice President of Marketing Activation for PepsiCo.
Multiple Myeloma Research Foundation Partners with Janssen Biotech, Inc. on Daratumumab Expanded Access Program
Jul 7 15
The Multiple Myeloma Research Foundation announced its collaboration with Janssen Biotech, Inc. on the daratumumab expanded access program, which launched for eligible multiple myeloma patients in the United States. Daratumumab is an investigational human anti-CD38 monoclonal antibody currently being evaluated as a potential multiple myeloma monotherapy treatment. EAPs allow pharmaceutical companies to make investigational therapies available to patients with serious or life-threatening diseases that are not helped by currently available treatment options. The multicenter, open-label daratumumab EAP is available to multiple myeloma patients who are double refractory to both a proteasome inhibitor and an immunomodulatory drug or who have received three or more prior lines of therapy. The MMRF has worked with Janssen in identifying sites across the U.S. and supporting its efforts for enrolling patients. Approximately half of the 40 medical centers involved in the EAP are MMRF partner institutions that comprise the Multiple Myeloma Research Consortium (MMRC). Previously in 2011, the MMRF partnered with Onyx Pharmaceuticals, Inc. on an EAP for carfilzomib (Kyprolis). The daratumumab EAP has specific inclusion and exclusion criteria for patients to be considered for enrollment in the program. Patients should contact their physician if they believe they are eligible or if they want to learn more.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|